UGE International

REGENERON PHARMACEUTICALS (NASDAQ: REGN) STOCK QUOTE

Last Trade: US$695.01 8.91 1.30
Volume: 645,437
5-Day Change: -2.84%
YTD Change: 10.05%
Market Cap: US$74.500B

LATEST NEWS FROM REGENERON PHARMACEUTICALS

Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28 NTLA-2001 was generally well-tolerated at both dose levels Intellia to discuss data at investor event today, Friday, September 16 , at 8:00 a.m. ET Intellia Therapeutics, Inc. (NASDAQ: NTLA ) and Regeneron... Read More
Dupixent is the first and only biologic that significantly improved skin clearance, and reduced itch and overall disease severity in children as young as 6 months old in a Phase 3 trial Published results reinforce well-established efficacy and safety profile of Dupixent across age groups Regeneron Pharmaceuticals, Inc . (NASDAQ: REGN) and Sanofi today announced that The Lancet has published positive results from a Phase 3... Read More
Target knockdown and safety results support continued clinical development Regeneron and Alnylam intend to initiate a Phase 2 study in late 2022 Detailed results to be presented at an upcoming medical congress Regeneron Pharmaceuticals (Nasdaq: REGN ) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY ) announced today preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic... Read More
63% combined pathologic response rate for neoadjuvant Libtayo monotherapy in stage II to IV resectable CSCC per primary analysis of a confirmatory Phase 2 trial Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo ® (cemiplimab) as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC). The data,... Read More
Positive clinical data presented in a mini-oral session at ESMO Safety profile of the combination was generally similar to Libtayo monotherapy Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive data from multiple expansion cohorts of an initial Phase 1 trial for an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo ® (cemiplimab) in advanced melanoma.... Read More
First-in-class Phase 1 data presented at ESMO for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive early data for two novel and investigational bispecific antibodies – ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to share updates on the company's oncology portfolio in conjunction with the European Society for Medical Oncology (ESMO) Annual Congress on Monday, September 12, 2022 . The webcast is scheduled for 8:00 AM ET ( 2:00 PM CEST ) and may be accessed from the "Investors & Media" page of Regeneron's website at... Read More
Nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions at 24 weeks compared to placebo There are currently no approved medicines specifically indicated to treat prurigo nodularis; regulatory submissions for Dupixent are under Priority Review in the U.S. and under review in the European Union 22 Dupixent abstracts are being presented at the EADV 2022 Congress across... Read More
91% and 89% of diabetic macular edema (DME) patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without need for regimen modification) through week 48, respectively 79% and 77% of wet age-related macular degeneration (wAMD) patients were rapidly initiated and maintained on 12- and 16-week dosing intervals (without need for regimen modification) through week 48, respectively Safety of... Read More
Results from the longest global Phase 3 open-label extension trial in this age group in asthma show sustained improvement in lung function, low rate of asthma attacks and a consistent safety profile for up to two years Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced results from a Phase 3 open-label extension trial demonstrating the efficacy and safety profile of Dupixent ® (dupilumab) as a... Read More
First-in-class Phase 1 data for two investigational bispecifics in advanced ovarian cancer and advanced MET-altered non-small cell lung cancer (NSCLC) to be presented Additional presentations include new data for investigational Libtayo monotherapy and combination therapies in advanced melanoma, NSCLC and cervical cancer, as well as neoadjuvant cutaneous squamous cell carcinoma Regeneron will host an investor webcast on... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: 2022 Wells Fargo Healthcare Conference at 11:00 a.m. ET on Thursday, September 8, 2022 Morgan Stanley 20 th Annual Global Healthcare Conference at 11:05 a.m. ET on Monday, September 12, 2022 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at... Read More
Second quarter 2022 revenues decreased 44% to $2.86 billion versus second quarter 2021; excluding REGEN-COV ® (a)(b) , revenues increased 20% Second quarter 2022 EYLEA ® U.S. net sales increased 14% versus second quarter 2021 to a record $1.62 billion Second quarter 2022 Dupixent ® global net sales (c) (recorded by Sanofi) increased 40% to $2.09 billion versus second quarter 2021 Second quarter 2022 GAAP diluted EPS of... Read More
First clinical data from ongoing Phase 1/2 trial show dose-dependent anti-tumor activity for investigational REGN5678 (PSMAxCD28) when combined with standard dose Libtayo, suggesting potential to overcome mCRPC resistance to PD-1 inhibition Anti-cancer activity correlated with immune-related adverse events These data provide early evidence and proof of principle for Regeneron's broader costimulatory bispecific platform,... Read More
New research published in The New England Journal of Medicine reveals that people with certain genetic loss-of-function mutations have more than 50% lower risk of nonalcoholic liver disease and nonalcoholic cirrhosis Regeneron and Alnylam have developed an siRNA therapeutic candidate targeting CIDEB that could enter clinical stages of development in the next year Unprecedented size of Regeneron Genetics Center human sequence... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 10th annual Regeneron Prize for Creative Innovation, a competition designed to recognize excellence and creativity in biomedical research conducted by postdoctoral fellows and graduate students. Each year, Regeneron invites the country's leading research universities to nominate early career scientists. Applicants present their "dream projects"... Read More
First and only investigational Phase 3 trial to show positive results in these young children; results follow recent approval of Dupixent in people with eosinophilic esophagitis aged 12 years and older who weigh at least 40 kilograms Trial met its primary endpoint, with 68% of patients on higher dose Dupixent and 58% on lower dose Dupixent achieving histological disease remission at 16 weeks Fifth pediatric pivotal trial... Read More
GreenStockNews
Ultima Genomics, Inc. (the Company) has signed an agreement with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) to further advance Ultima Genomics' sequencing architecture. Under the terms of the agreement, Regeneron will collaborate with Ultima on the development and testing of Ultima's second-generation sequencing platform,... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2022 financial and operating results on Wednesday, August 3, 2022 , before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media'... Read More
Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has completed the acquisition of Sanofi's stake in Libtayo ® (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in... Read More
If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the EYLEA ® (aflibercept) Injection supplemental Biologics License Application (sBLA) for an every 16-week 2 mg dosing regimen (after... Read More
Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose, where treatment with NTLA-2001 resulted in 93% mean and 98% maximum serum TTR reduction by day 28 Intellia to host investor event to... Read More
Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced itch compared to TCS alone at week 16 in a Phase 3 trial Long-term safety data from a 52-week open-label extension trial in this age group reinforce the well-established safety profile of Dupixent observed across all other approved age groups Dupixent is... Read More
Regeneron will secure global rights to Libtayo from Sanofi in exchange for upfront payment of $900 million , plus royalties and potential future milestone payments 18 different investigational treatment combinations with Libtayo currently being evaluated in 22 clinical trials Regeneron will host an investor conference call today at 8:30 am ET ; dial-in details are available below Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN... Read More
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ: CMPI) by Regeneron Pharmaceuticals (NASDAQ: REGN). The completion triggers a $5 million milestone... Read More
Acquisition strengthens Regeneron's innovative portfolio of immuno-oncology candidates and diversified approach to cancer treatment Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it has successfully acquired Checkmate Pharmaceuticals, Inc., deepening its commitment to immuno-oncology and adding a new modality to the company's portfolio of potential combination-ready approaches for difficult-to-treat... Read More
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ® Medical (dupilumab) to treat adults with prurigo nodularis, a chronic skin disease... Read More
Children already on other lipid-lowering therapies entered the trial with dangerously high LDL-C (264 mg/dL on average), and 79% saw their LDL-C reduced by at least half at 24 weeks FDA submission planned by end of 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced positive results from a Phase 3 trial evaluating Evkeeza ® (evinacumab) in children aged 5 to 11 with homozygous familial hypercholesterolemia... Read More
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States ; approval granted more than two months ahead of FDA's Priority Review action date Dupixent 300 mg weekly significantly improved signs and symptoms of eosinophilic esophagitis compared to placebo in a Phase 3 trial, underscoring the role of type 2 inflammation in this complex disease Eosinophilic esophagitis is a chronic,... Read More
Vyriad, Inc. , a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc. with participation from existing investors. Stine Seed Farms joins Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals Inc., Southeast Minnesota Capital Fund (SMCF), and several high-net-worth individuals on the... Read More
$75,000 Top Award Goes to 17-year-old Robert Sansone for pioneering invention to improve electric motor efficiency in the largest international STEM competition for teens Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Robert Sansone , 17, of Fort Pierce, FL , won the $75,000 top award in the 2022 Regeneron International Science and Engineering Fair (Regeneron ISEF), the... Read More
First quarter 2022 revenues increased 17% to $2.97 billion versus first quarter 2021; excluding REGEN-COV ® (a)(b) , revenues increased 25% First quarter 2022 EYLEA ® U.S. net sales increased 13% to $1.52 billion versus first quarter 2021 First quarter 2022 Dupixent ® global net sales (c) (recorded by Sanofi) increased 43% to $1.81 billion versus first quarter 2021 First quarter 2022 GAAP diluted EPS of $8.61 ; non-GAAP... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: BofA Securities Healthcare Conference at 1:20 p.m. PT ( 4:20 p.m. ET ) on Tuesday, May 10, 2022 Goldman Sachs 43 rd Annual Global Healthcare Conference at 8:40 a.m. PT (11:40 a.m . ET) on Tuesday, June 14, 2022 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at... Read More
Proposed ~$250 million all-cash acquisition strengthens Regeneron’s portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and... Read More
Regeneron continues to progress its next generation antibodies, and has initiated a first-in-human trial Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended by three months its review of the Biologics License Application (BLA) for REGEN-COV ® (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain... Read More
Approval based on Phase 3 data showing Dupixent significantly reduced severe asthma attacks and also improved lung function and health-related quality of life for children Data reinforce well-established safety profile of Dupixent Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent ® (dupilumab) in the European... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2022 financial and operating results on Wednesday, May 4, 2022 , before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media' page... Read More
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis There are approximately 160,000 patients in the U.S. living with eosinophilic esophagitis who are currently treated, of whom approximately 48,000 have failed multiple treatments Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has accepted for... Read More
Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three times as many Dupixent patients experienced clinically meaningful reductions in itch and skin lesions There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for Dupixent in prurigo nodularis are planned in the first half of 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi announced that detailed... Read More
$250,000 top award goes to Christine Ye in the nation's oldest and most prestigious science and math competition for high school seniors Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced the top ten winners headed by Christine Ye , 17, of Sammamish, Wash. , who won the top award in the 2022 Regeneron Science Talent Search , the nation's oldest and most prestigious science and math... Read More
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levels Durable serum TTR reductions observed with patient follow-up ranging from 2 to 12 months NTLA-2001 was generally well tolerated at all dose levels On track to initiate polyneuropathy dose-expansion cohort (Part 2) in Q1 2022 Intellia to host investor event... Read More
In this Phase 3 trial, Dupixent added to standard-of-care antihistamines nearly doubled reduction in itch and urticaria activity scores compared to standard-of-care alone at 24 weeks in biologic-naïve patients uncontrolled on antihistamines Data reinforce the potential of targeting IL-4 and IL-13, key drivers of type 2 inflammation, in this complex chronic disease Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi... Read More
Dupixent 300 mg weekly is the only biologic medicine to show positive, clinically meaningful Phase 3 results in adults and adolescents with eosinophilic esophagitis Eosinophilic esophagitis is a chronic, progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly U.S. and global regulatory filings are planned in 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today... Read More
In a Phase 3 trial in patients refractory to omalizumab, Dupixent did not reach statistical significance in interim analysis despite numeric improvements observed across key endpoints; trial will be stopped due to futility Positive results from a previous Phase 3 trial in biologic-naïve patients showed Dupixent significantly reduced itch and hives compared to standard-of-care antihistamines alone Companies remain committed... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: Cowen 42 nd Annual Health Care Conference at 1:30 p.m. ET on Tuesday , March 8, 2022 Oppenheimer 32 nd Annual Healthcare Conference at 10:00 a.m. ET on Tuesday , March 15, 2022 Barclays Global Healthcare Conference at 8:00 a.m. ET on Wednesday, March 16, 2022 The sessions may be accessed from the "Investors & Media" page of... Read More
Trial met primary safety endpoint and no new safety signals seen through week 44 Results favored aflibercept 8 mg in visual acuity, drying and other anatomical measures through week 44 Phase 3 results in wet age-related macular degeneration and diabetic macular edema expected in the second half of 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced results from its Phase 2 proof-of-concept trial evaluating... Read More
If approved, Dupixent will be the first biologic medicine available in the U.S. to treat uncontrolled moderate-to-severe atopic dermatitis for these young children Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) as an add-on maintenance... Read More
Fourth quarter 2021 revenues increased 104% to $4.95 billion versus fourth quarter 2020 including $2.30 billion attributable to REGEN-COV ® (2) ; revenues excluding REGEN-COV (1) increased 17% Full year 2021 revenues increased 89% to $16.07 billion compared to full year 2020 including $6.19 billion attributable to REGEN-COV (2) ; revenues excluding REGEN-COV (1) increased 19% Fourth quarter 2021 EYLEA ® U.S. net sales... Read More
GreenStockNews
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today named 40 finalists in this year's Regeneron Science Talent Search , the nation's oldest and most prestigious science and math competition for high school seniors. Program alumni include recipients of the world's most coveted science and... Read More
Regulatory filing recently submitted in the European Union Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo ® (cemiplimab-rwlc) in combination with chemotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC). The target action date for... Read More
Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions Data confirm results from first Phase 3 trial, with 60% of Dupixent patients meeting the primary endpoint of itch reduction compared to 18% of placebo patients at 24 weeks Additionally,... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2021 financial and operating results on Friday, February 4, 2022 , before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Ultragenyx Pharmaceutical Inc. today announced a license and collaboration agreement for Ultragenyx to clinically develop, commercialize and distribute Evkeeza ® (evinacumab) in countries outside of the U.S. This includes the European Economic Area, where Evkeeza was approved in June 2021 as a first-in-class therapy for use together with diet and other low-density... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast its presentation at the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10 , 2022. The presentation is scheduled for 10:30 a.m. Eastern Time and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations . An archived version of the presentation will be available for at least... Read More
Dupixent significantly improved skin clearance and reduced overall disease severity and itch in pivotal trial that met all primary and secondary endpoints Global regulatory filings planned in the coming months, starting with the U.S. by the end of 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced detailed positive Phase 3 results that showed adding Dupixent ® (dupilumab) to standard-of-care... Read More
Includes latest data for REGN5458, including in highest dose levels (200-800 mg) Among patients who responded across all dose groups (3-800 mg), there was a 90% probability of being event-free (i.e., alive without disease progression) 8 months from the time of response Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced new results for higher dose level cohorts of its investigational REGN5458 (BCMAxCD3)... Read More
Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma Published results reinforce well-established safety profile of Dupixent Positive data formed the basis for FDA approval of Dupixent in these patients with certain types of moderate-to-severe asthma and regulatory reviews are ongoing in the European Union... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C. Wainwright & Co. event – Unlocking the Full Potential of RNAi With World-Class Novel Target Identification: Regeneron Genomics and Alnylam's RNAi Platform Collaboration Update – at 2:00 p.m. ET on Monday, December 6, 2021 . Aris Baras , M.D., Senior Vice President at Regeneron and Head of the Regeneron Genetics... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Evercore ISI 4 th Annual HealthCONx Conference at 9:15 a.m. ET on Tuesday, November 30, 2021 Piper Sandler 33 rd Annual Healthcare Conference at 8:00 a.m. ET on Wednesday , December 1, 2021 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at... Read More
DJSI World highlights the most sustainable companies around the world by industry Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been recognized as a global corporate responsibility leader through inclusion on the Dow Jones Sustainability World Index (DJSI World) for the third year in a row. Regeneron was also named to the Dow Jones Sustainability North America Index (DJSI North America) for the second time. DJSI World... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that its Board of Directors authorized a share repurchase program of up to $3 billion of the Company's outstanding common stock. "With the strength of our balance sheet and our business, we see this as an opportunity to continue to invest in Regeneron," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron. "This share... Read More
EC marketing authorization follows approvals in Japan , Australia and the UK Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the European Commission (EC) has approved the casirivimab and imdevimab antibody cocktail, known as REGEN-COV ® in the U.S. and Ronapreve ™ in the European Union (EU) and other countries. The EC granted marketing authorization for the antibody cocktail for people aged 12 years and... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the casirivimab and imdevimab antibody cocktail, known as REGEN-COV ® in the U.S. and Ronapreve™ in the European Union (EU) and other countries. The positive opinion is for people aged 12 years and older for the treatment of... Read More
Single dose of REGEN-COV (1,200 mg subcutaneous) reduced the risk of COVID-19 by 81.6% during the pre-specified follow-up period (months 2-8), maintaining the 81.4% risk reduction previously reported during month 1 During the 8-month assessment period there were 0 hospitalizations for COVID-19 in the REGEN-COV group and 6 in the placebo group The fully human antibodies in REGEN-COV were developed to provide long-lasting... Read More
New data for REGN5458 (BCMAxCD3 bispecific antibody) in patients with heavily pre-treated multiple myeloma to be highlighted in an oral presentation First data evaluating a combination therapy approach with pozelimab (C5 antibody) and Alnylam's cemdisiran (siRNA C5 inhibitor) in healthy volunteers Regeneron will host an investor webcast on Monday, December 13 to provide further updates across its hematology portfolio... Read More
Third quarter 2021 revenues increased 51% to $3.45 billion versus third quarter 2020 including $804 million attributable to REGEN-COV ® (2) Third quarter 2021 EYLEA ® U.S. net sales increased 12% versus third quarter 2020 to $1.47 billion Third quarter 2021 Dupixent ® global net sales (3) , which are recorded by Sanofi, increased 55% to $1.66 billion versus third quarter 2020 Third quarter 2021 GAAP diluted EPS was $14.33... Read More
Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial Eosinophilic esophagitis is a progressive disease that damages the esophagus and impairs the ability to swallow; 90% of trial participants had at least one coexisting type 2 inflammatory condition such as asthma or atopic dermatitis Dupixent... Read More
Pivotal trial met primary and all key secondary endpoints Dupixent significantly reduced itch at 12 weeks, and nearly three times as many Dupixent patients experienced reductions in both itch and skin lesions at 24 weeks Prurigo nodularis, the sixth disease where Dupixent has demonstrated positive Phase 3 results, is a chronic skin condition that causes extreme itch and inflammatory skin lesions (nodules) Data reinforce... Read More
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option Only biologic medicine approved for children with oral corticosteroid-dependent asthma Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) as an... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a Biologics License Application (BLA) for REGEN-COV ® (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. The FDA has assigned a target action date of April 13, 2022 and informed us that they currently are planning... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2021 financial and operating results on Thursday, November 4, 2021 , before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the 'Investors and Media'... Read More
Trial met primary endpoint, showing REGEN-COV significantly reduced viral load within 7 days of treatment; trial conducted in patients hospitalized with COVID-19 who did not require high-flow oxygen or mechanical ventilation at baseline Numeric improvements with REGEN-COV observed for all clinical endpoints, including a 36% reduced risk of death by day 29 in the overall population, increasing to 56% reduced risk in patients... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine ( NEJM ) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to treat COVID-19 in infected high-risk non-hospitalized patients (outpatients). The trial met its primary and all secondary endpoints and showed treatment with REGEN-COV significantly... Read More
European Union regulatory submission planned by end of 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for PD-1 inhibitor Libtayo ® (cemiplimab-rwlc) to treat patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy. The... Read More
More than 30 presentations reinforce the role of Dupixent in targeting IL-4 and IL-13, key drivers of the type 2 inflammation underlying atopic dermatitis in children, adolescents and adults Results provide insight into the clinical and real-world experience of Dupixent on disease measures including itch, disease severity, sleep, and anxiety Dupixent presentations include longest duration of data for any biologic medicine in... Read More
Phase 3 trial met its primary and key secondary endpoints Libtayo is one of two PD-(L)1 inhibitors to demonstrate positive Phase 3 results in first-line advanced NSCLC irrespective of histology both as monotherapy and in combination with chemotherapy Trial enrolled patients with varied baseline characteristics, including squamous and non-squamous histologies and all PD-L1 expression levels; 84% had an ECOG 1 performance... Read More
New agreement for 1.4 million doses of REGEN-COV, brings total purchased by the U.S. government to nearly 3 million doses REGEN-COV currently authorized to treat certain infected patients to reduce risk of hospitalization or death from COVID-19, and for post-exposure prophylaxis for close contacts of infected individuals Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the U.S. Department of Health and... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: Morgan Stanley 19 th Annual Global Healthcare Conference at 8:45 a.m. ET on Monday , September 13, 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 9:20 a.m. ET on Monday , September 27, 2021 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at... Read More
Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks More than seven times as many patients treated with Dupixent plus topical corticosteroids (TCS) achieved clear or almost clear skin compared to TCS alone at week 16 Dupixent plus TCS reduced overall disease severity by 70% and itch by 49% Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced... Read More
Phase 3 trials in wet AMD and diabetic macular edema fully recruited, with results expected in the second half of 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA ® (aflibercept)... Read More
UK chief medical officers to confirm how antibody cocktail will be rolled-out on the National Health Service (NHS) in the coming weeks In the U.S., Regeneron has completed the first FDA BLA submission for the antibody cocktail; more than 130,000 doses were distributed in the past week to address COVID-19 outbreaks Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the United Kingdom's (UK) Medicines and... Read More
Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-COV TM(2) ; revenues excluding REGEN-COV (1)(2) increased 22% Second quarter 2021 EYLEA ® U.S. net sales increased 28% versus second quarter 2020 to a record $1.42 billion Second quarter 2021 Dupixent ® global net sales (3) , which are recorded by Sanofi, increased 59% to $1.50 billion versus... Read More
Libtayo combined with chemotherapy increased median overall survival from 13 to 22 months, leading to a 29% reduction in the risk of death Trial enrolled patients with locally advanced and metastatic disease with squamous or non-squamous histology, across all PD-L1 expression levels Libtayo has now demonstrated improved overall survival as a monotherapy or in combination with chemotherapy in first-line advanced non-small... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the New England Journal of Medicine ( NEJM ) published positive detailed results from a Phase 3 trial that assessed the ability of REGEN-COV™ (casirivimab and imdevimab) to prevent COVID-19 infection among household contacts of SARS-CoV-2 infected individuals. The trial met its primary endpoint, reducing the risk of symptomatic infections by 81% (pRead More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced winners of the ninth annual Regeneron Prize for Creative Innovation, a competition designed to recognize creativity and independent scientific thinking among postdoctoral fellows and graduate students focused on biomedical research. Each year, the country's leading research universities are invited to nominate top candidates, who then attend a virtual... Read More
Expanded authorization enables use of REGEN-COV for post-exposure prophylaxis in certain people exposed to a SARS-CoV-2 infected individual, or who are at high risk of exposure to an infected individual in an institutional setting Supported by pivotal Phase 3 data showing 81% reduced risk of symptomatic infections in close contacts of SARS-CoV-2 infected individuals Only COVID-19 antibody therapy currently available across... Read More
Fifth disease in which Dupixent has demonstrated positive pivotal results Phase 3 trial met primary and all key secondary endpoints at 24 weeks, showing Dupixent nearly doubled reduction in itch and urticaria activity scores CSU results further demonstrate the potential of targeting IL-4 and IL-13 via IL-4Ra blockade to improve diseases with components of type 2 inflammation Approximately 300,000 people in the U.S. have... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and AstraZeneca today announced that the companies have entered into a collaboration to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. The collaboration builds on the recent discovery from the Regeneron Genetics Center ® of rare genetic mutations in the GPR75 gene... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Regeneron's casirivimab and imdevimab antibody cocktail to treat patients with mild to moderate COVID-19. This marks the first time the antibody cocktail, known as REGEN-COV TM in the U.S. and Ronapreve™ in other countries, has received a full approval to treat COVID-19. Emergency or... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2021 financial and operating results on Thursday, August 5, 2021 , before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International),... Read More
Publication in Science reports that people with these protective mutations have 54% reduced risk of obesity Regeneron used its VelociGene ® technology to create mice with similar protective mutation that are resistant to obesity Regeneron already creating potential therapeutics to fight obesity using its VelocImmune ® technology and collaborator Alnylam's siRNA technology Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today... Read More
Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency will update the Dupixent ® (dupilumab) summary of product characteristics (SmPC) adding long-term safety results for adults with moderate-to-severe atopic dermatitis based on a positive opinion by the Committee for Medicinal Products for Human Use (CHMP). Data from a single-arm Phase 3 open label extension (OLE)... Read More
First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean reduction in serum TTR, with a maximum 96% serum TTR reduction by day 28, with dose-dependent response Encouraging safety profile; no serious adverse events observed in the first six patients by day 28 Data published in The New... Read More
Approval based on data from the largest trial to date in patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor Libtayo now approved by the European Commission for three advanced cancers Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Sanofi today announced that the European Commission (EC) has approved the PD-1 inhibitor Libtayo ® (cemiplimab) to treat adults with locally... Read More
Approval based on a Phase 3 trial demonstrating Libtayo significantly improved overall survival compared to chemotherapy in advanced NSCLC that included challenging-to-treat patient populations Libtayo now approved by the European Commission for three advanced cancers Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved the PD-1 inhibitor Libtayo ®... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the Guggenheim Biopharma Strategy Series – Biopharma's Next Decade: Views from the Top on Global Strategy and Innovation – at 10:00 a.m. ET on Tuesday , June 29, 2021. A live audio webcast will be available on the 'Investors and Media' page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.... Read More
UK RECOVERY investigators found REGEN-COV reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response (primary outcome for the primary analysis population) First trial to demonstrate that any antibody treatment improved survival in patients hospitalized with COVID-19 Regeneron will share new data with regulatory authorities immediately and request that the U.S. EUA be... Read More
EUA supported by pivotal Phase 3 data showing 1,200 mg dose reduced risk of hospitalization or death by 70% Only antibody therapy currently available in all 50 states, including eight states with high rates of two variants of concern Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) updated the Emergency Use Authorization (EUA) for REGEN-COV™, lowering the dose to... Read More
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) will webcast management participation as follows: Bernstein's 37 th Annual Strategic Decisions Conference at 8:00 a.m. ET on Wednesday , June 2, 2021 Goldman Sachs 42 nd Annual Global Healthcare Conference at 10:30 a.m. ET on Tuesday, June 8, 2021 BMO Biopharma Day at 8:00 a.m. ET on Tuesday , June 22, 2021 The sessions may be accessed from the "Investors & Media" page of... Read More
Libtayo recommended for approval in the first-line treatment of certain patients with advanced non-small cell lung cancer whose tumors have ≥50% PD-L1 expression Libtayo also recommended for approval in patients with advanced basal cell carcinoma who have progressed on or are intolerant to a hedgehog pathway inhibitor CHMP has now issued three positive opinions for Libtayo in advanced cancers Regeneron Pharmaceuticals, Inc.... Read More

COPYRIGHT ©2022 GREEN STOCK NEWS